Submit Request Quote
 * Denotes Required Field.
Company Name:
Request Quote
Out Of Stock image

Is currently out of stock, however if you enter your email address we will notify you when it comes back into stock!

Search: Search


Recorded on Sep 19, 2023 Noon – 1 pm Eastern

Real World Efficacy of Cell- and Egg-Based Quadrivalent Influenza Vaccines in Adults During the U.S. 2019-2020 Influenza Season

By Brandon Young Ph.D.



Member: $25

Non-Member: $45  


Join now to become AOHP member to enjoy the FREE live webinar member benefit. Click here to download the membership application form or join online


Topic Overview:

Mutations occurring during egg-based influenza vaccine production may affect vaccine effectiveness. The mammalian cell-based quadrivalent inactivated influenza vaccine (IIV4c) demonstrated improved protection relative to egg-based vaccines in prior seasons. This study estimated the relative vaccine effectiveness (rVE) of IIV4c versus standard-dose egg-based quadrivalent inactivated influenza vaccine (IIV4e) in preventing influenza-related medical encounters (IRME) in the 2019-2020 US influenza season. This retrospective cohort study used electronic medical records linked to pharmacy and medical claims. Subjects included those aged ≥18 years vaccinated with IIV4e or IIV4c during 2019-2020 influenza season. The outcome was occurrence of IRMEs (inpatient or outpatient) defined by diagnostic codes specific to influenza (ICD-10 codes J09*–J11*). We used a doubly robust inverse probability of treatment weighting model to obtain odds ratios (OR) adjusted for age, sex, race, ethnicity, region, vaccination week, health status, frailty and baseline healthcare resource utilization. rVE was calculated by (1–OR adjusted)*100. An exploratory analysis evaluated IRME in inpatient and outpatient settings separately. The final study cohort included 1,499,215 IIV4c and 4,126,263 IIV4e recipients ≥18 years of age. Fewer IRMEs were reported in individuals with recorded IIV4c vs IIV4e. The rVE for

IIV4c vs IIIV4e for any IRME was 9.5% (95% CI 7.9 to 11.1). Inpatient and outpatient rVEs were 5.7% (2.1 to 9.2) and 11.4% (9.5 to 13.3), respectively. In age subgroup analyses, rVEs favored IIV4c except in adults ≥65 years. Adults vaccinated with IIV4c had a lower risk of IRME vs IIV4e recipients in the 2019-2020 US influenza season. These results support IIV4c as a potentially more effective than egg-based vaccines as public health measure against influenza.


Objective 1: Understand the relative vaccine effectiveness (rVE) of cell-based quadrivalent inactivated influenza vaccine (QIVc) compared with egg-based quadrivalent inactivated influenza vaccine (QIVe) in preventing cardio-respiratory hospitalizations in individuals 18–64 years of age in the U.S. 2019–20 influenza season.


Objective 2: Compare the rVE of QIVc vs. QIVe in age subgroups 18 – 49 and 50 – 64 years of age in the U.S. 2019-20 influenza season.


Objective 3: Recognize the rVE of QIVc vs. QIVe in preventing respiratory-related hospitalizations in children 417 years of age in the U.S. 2019-20 influenza season.


Speaker Bio:

 Dr. Young is the Mid-Atlantic Medical Science Liaison for CSL Seqirus. He completed his Ph.D. in Biochemistry and Molecular Biology at the Medical University of South Carolina (MUSC), with a focus on drug design against antimicrobial resistant bacteria. He then matriculated to Emory University for his Post-Doctoral research where he was a Fellowships in Research and Science Teaching Scholar. His research focused on drug and vaccine design for Ebola virus. At CSL Seqirus we have a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies, and the latest methods of production and distribution.




Requirements for Completion

Successful completion of this activity includes submitting an accurate registration, making necessary payment, and reviewing all activity slides and the webinar presentation. Completion of the evaluation form is required.


Type of Activity: Knowledge


Disclosures: AOHP does not guarantee, warrant, certify, verify, and/or authorize the content of this seminar, and/or any subsequent use of the information presented at this webinar. This webinar is not a clinical/medical service but is intended for educational purposes only. Planners of this educational activity have no real or apparent financial, professional or personal conflict of interest to disclose. Faculty/presenter disclosure is stated following each presenter’s bio-sketch. AOHP has implemented a mechanism to identify and resolve all conflicts of interest before the delivery of this educational activity.


Commercial or Sponsor Support: N/A

Continuing education Contact Hour: This activity awards one (1) contact hour.


Provider approved by the California Board of Registered Nursing, Provider Number CEP 17664.


Conflict of Interest: A conflict of interest occurs when an individual has an opportunity to affect educational content about healthcare products or services of a commercial company with which she/he has a financial, professional or personal relationship.


The planners and presenter(s)/author(s) of this education activity have disclosed no relevant financial, professional or personal relationships with any commercial companies about this activity.


Non-Endorsement of Products: The Association of Occupational Health Professionals in Healthcare's accredited provider status refers only to continuing education activities and does not imply that there is real or implied endorsement of any product, service or company referred to in this activity nor of any company subsidizing costs related to the activity.


$45.00 - $45.00 Tax Incl.


    AOHP MEMBERS: Please login to receive member-only discount rates!

    Cart Summary
   : 0
    Subtotal: $0.00